The FDA has approved the use of Liletta (levonorgestrel-releasing intrauterine system; Allergan and Medicines360) for the prevention of pregnancy for up to 6 years. Previously, the progestin-containing intrauterine device was indicated for up to 5 years of use.
Farxiga has been approved to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
An intermittent fasting diet may be beneficial for reducing body mass index (BMI) and improving glycemic control, according to a recent systematic review and meta-analysis published in the Journal of Clinical Medicine.
The FDA has accepted for priority review the Biologics License Application (BLA) for teprotumumab (Horizon Therapeutics) for the treatment of active thyroid eye disease.
Results showed that those with private insurance were more likely than those with Medicaid to request a lower-cost alternative.
The meta-analysis included 101,642 patients with osteoporosis.
Prescription drug use appears to be similar in the US and Canada, according to a new data brief from the Centers for Disease Control and Prevention (CDC).
Results from a phase 3 trial evaluating the efficacy of evinacumab (Regeneron) in the treatment of patients with homozygous familial hypercholesterolemia (HoFH) showed that the investigational angiopoietin-like 3 (ANGPTL3) antibody reduced low-density lipoprotein (LDL) cholesterol by 49%.
